FDA Approves Nivolumab with Ipilimumab for Unresectable or Metastatic MSI-H or dMMR Colorectal Cancer By Ogkologos - May 9, 2025 421 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the CHECKMATE-8HW study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Lurbinectedin Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian MOST POPULAR FDA Approves Amivantamab and Hyaluronidase-lpuj for Subcutaneous Injection January 14, 2026 Family Starts “Dancing While Cancering” To Honor Their Daughter’s Joyful Memory. October 9, 2019 Tough questions for tough times in clinical research April 29, 2022 Toothbrushes and ctDNA: Exciting early detection concepts from new teams formed... May 11, 2022 Load more HOT NEWS Reunión anual de la American Society of Clinical Oncology de 2022:... ScottishPower help us shine a light on air pollution and cancer Detecting multiple cancers with a ‘simple’ blood test: Where are we? Analyzing Tumor RNA May Help Match Patients with Most Effective Cancer...
